LongBio Pharma

LongBio Pharma is a Phase III-stage biotech company developing innovative antibody and fusion protein drugs for allergies and complement-mediated diseases. They leverage a proprietary technology platform to create biologics with independent intellectual property rights, such as LP-003, a high-affinity anti-IgE antibody, and LP-005, a bi-functional anti-C3&C5 antibody. These drugs aim to offer superior efficacy and cost-effectiveness compared to existing treatments.


Buy Funded Startups lists

Funding Round: Series B2

Funding Amount:

Date: 24-Sep-2024

Investors: Qiming Venture Partners

Markets: Biotechnology, Pharmaceuticals, Medical

HQ: Suzhou, Jiangsu, China

Founded: 2020

Website: http://www.longbio.com/

LinkedIn:

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/longbio-pharma

Pitchbook:


Leave a Comment